<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189695</url>
  </required_header>
  <id_info>
    <org_study_id>BIDI-MONO</org_study_id>
    <nct_id>NCT01189695</nct_id>
  </id_info>
  <brief_title>Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure</brief_title>
  <acronym>BIDI-MONO</acronym>
  <official_title>A Randomized Controlled Study Compares the 48 Weeks Results of HIV-1 RNA Between Ritonavir-boosted Lopinavir Monotherapy and Ritonavir-boosted Lopinavir + Optimized Background Regimens in HIV-1 Infected Patients Who Have HIV-1 RNA &lt;50 Copies/ml More Than 6 Months While Receiving Salvage PI-based Regimen and Previously Failed NNRTI-based Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bamrasnaradura Infectious Diseases Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Disease Control, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bamrasnaradura Infectious Diseases Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine efficacy of ritonavir-boosted lopinavir
      monotherapy as a maintenance regimen in HIV-1-infected patients who previously failed
      Non-nucleoside reverse transcriptase inhibitors (NNRTI) based regimens and currently received
      salvage protease-inhibitor (PI) based regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to virological failure</measure>
    <time_frame>48 weeks</time_frame>
    <description>virological failure was defined as having two consecutive results of HIV-1 RNA &gt;400 copies/ml in time separated by 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with virological suppression</measure>
    <time_frame>48 weeks</time_frame>
    <description>virological suppression defined as having HIV-1 RNA &lt;40 copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with virological failure</measure>
    <time_frame>48 week</time_frame>
    <description>virological failure was defined as having two consecutive results of HIV-1 RNA &gt;400 copies/ml in time separated by 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of virological response (TLOVR)</measure>
    <time_frame>48 weeks</time_frame>
    <description>TLOVR was defined as time between randomization and the last value that HIV-1 RNA &lt;40 copies/ml in a patient who initially suppressed HIV-1 RNA but subsequently demonstrated virologic rebound (two consecutive HIV-1 RNA &gt;40 copies/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CD4 cells count</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change of CD4 cells count from start of study to Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 weeks</time_frame>
    <description>any grade 3 or grade 4 adverse events according to DAIDS AE grading table</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <condition>Lopinavir</condition>
  <condition>Treatment Failure</condition>
  <arm_group>
    <arm_group_label>Boosted lopinavir monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>boosted lopinavir + optimized background regimens (OBRs)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir-boosted lopinavir</intervention_name>
    <description>Lopinavir/ritonavir 200/50 mg every 12 hours</description>
    <arm_group_label>Boosted lopinavir monotherapy</arm_group_label>
    <arm_group_label>boosted lopinavir + optimized background regimens (OBRs)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>optimized background regimens (OBRs)</intervention_name>
    <description>Optimized background regimens such as NRTIs, etravirine or raltegravir</description>
    <arm_group_label>boosted lopinavir + optimized background regimens (OBRs)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-60 years

          -  documented HIV infection

          -  previously failed to NNRTI-based regimens

          -  no history of failing PI-based regimens

          -  receiving ritonavir-boosted PI + OBRs(such as NRITs, etravirine, raltegravir)

          -  having HIV-1 RNA &lt;50 copies/ml for at least prior 6 months

        Exclusion Criteria:

          -  Pregnant or breastfeeding woman

          -  HBV co-infection that had to treated with TDF, FTC or 3TC

          -  had to received medications known to have potential significant drug interaction with
             LPV/r

          -  life expectancy less than 6 months

          -  serious systemic diseases such as liver cirrhosis Child-Pugh B/C, ESRD, malignancy

          -  hemoglobin &lt;8 g/dl, platelet &lt;50,000/mm3, AST or ALT &gt;3 ULN, estimated creatinine
             clearance &lt;50 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krittaecho Siripassorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bamrasnaradura Infectious Diseases Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Diseases Institute</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2010</study_first_posted>
  <last_update_submitted>May 10, 2013</last_update_submitted>
  <last_update_submitted_qc>May 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bamrasnaradura Infectious Diseases Institute</investigator_affiliation>
    <investigator_full_name>Krittaecho Siripassorn</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>HIV or AIDS</keyword>
  <keyword>Lopinavir</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Anti-Retroviral Agents</keyword>
  <keyword>treatment failure</keyword>
  <keyword>treatment experienced</keyword>
  <keyword>NNRTI failure</keyword>
  <keyword>monotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

